NTX-301

A Phase 1 Study of NTX-301, an Oral DNMT1 Inhibitor, in Patients With MDS and AML

Arms / Cohorts

Experimental:NTX-301

Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.